Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. FDA approves trial for J&J’s Mentor MemoryGel breast implant
Johnson & Johnson subsidiary Mentor Worldwide said it won FDA investigational device exemption approval for its Athena clinical trial testing its Mentor MemoryGel breast implants.
The Mentor MemoryGel beast implants are designed for breast reconstruction patients with larger chest widths, larger breast sizes, higher BMI or greater amounts of removed mastectomy tissue, the company said. Read more
2. Direct Flow debuts transcatheter mitral valve
Direct Flow Medical said it premiered its transcatheter mitral valve, developed as part of its TMV development program. The debut was made at the 2nd annual Zurich Heart Team Mitral Valve meeting.
The valve is designed to be repositionable and retrievable, and is built upon Direct Flow’s transcatheter aortic valve, the Santa Rosa, Calif.-based company said. Read more
1. Stryker to pay $1.3B for Physio-Control
Stryker said that it agreed to pay $1.28 billion to Bain Capital for automated external defibrillator maker Physio-Control.
Medtronic sold Physio-Control to Bain for $478 million in January 2012. Read more
The post MassDevice.com +3 | The top 3 medtech stories for February 16, 2016 appeared first on MassDevice.
from MassDevice http://ift.tt/1PZM9EH
Cap comentari:
Publica un comentari a l'entrada